Shares of Anbio Biotechnology (NASDAQ:NNNN – Get Free Report) reached a new 52-week low on Thursday . The company traded as low as $6.55 and last traded at $6.51, with a volume of 64932 shares trading hands. The stock had previously closed at $6.85.
Analysts Set New Price Targets
Separately, Weiss Ratings lowered Anbio Biotechnology from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Wednesday, July 29th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Sell”.
View Our Latest Research Report on Anbio Biotechnology
Anbio Biotechnology Price Performance
Anbio Biotechnology Company Profile
Anbio Biotechnology is dedicated to the advancement of medical technology and the provision of in vitro diagnostics (IVD) products. Our unwavering commitment lies in transforming the diagnostics landscape on a global scale, fostering a paradigm shift towards personalized and decentralized diagnostic solutions. By doing so, we aim to significantly enhance patient prognosis and contribute to the betterment of healthcare worldwide. At Anbio Biotechnology, our extensive portfolio comprises an array of IVD products designed to cater to diverse diagnostic needs.
Read More
- Five stocks we like better than Anbio Biotechnology
- Revolution Medicines Got Its Breakthrough—What Moves It Next?
- Retail Earnings Just Exposed a Bigger Divide in the U.S. Consumer Economy
- FB Financial’s Southern Expansion and Buybacks Drive Analyst Optimism
- AST SpaceMobile Stock Soared 12%—This Was the Catalyst
Receive News & Ratings for Anbio Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anbio Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.
